Skip to main content
Log in

The scientific establishment of a new therapeutic intervention for developmental conditions: practical and ethical principles

  • Invited Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Background

Although the randomized controlled trial (RCT) is a major methodological breakthrough extending the limits of objectivity in clinical medical science, clinical trials of surgery have seldom included placebo surgery as a control, for ethical reasons. Especially in clinical studies intended eventually to establish a new intervention for developmental conditions, it has been recognized that there is huge examiner bias. In addition, the many miraculous cases that have been reported in nonsurgical open trials for developmental conditions and have eventually been evaluated as nonspecific positive outcomes in RCTs suggest that empirically promising interventions must be subjected to scientific scrutiny as soon as possible in the field of developmental conditions.

Application to pediatric neurosurgery

Therefore, in childhood neurosurgery, clinical studies to establish a new therapeutic measure for developmental conditions should be designed as rigorously as possible using optimized scientific methods. The worldwide ethical guideline, the Declaration of Helsinki issued by the World Medical Association, can provide principles for the establishment of a new intervention in the treatment of a patient when proven therapeutic methods do not exist or methods used thus far have been ineffective. Physicians’ discretion to use unproven or new therapeutic measures for such patients is approved in the presence of efforts of an ethical and scientific approach. Even if the measure is a very promising intervention, the research aspects must completely be demonstrated for informed consent and review by the ethical committee and the trial must be regarded as a clinical research. Especially when an RCT is not possible for ethical reasons, appropriate epidemiological data or animal experiments should suggest that the new measure is effective before a clinical trial. In a clinical setting, where neither epidemiological studies nor animal experimentation can be introduced, if necessary the researcher should collaborate with experts to obtain multidisciplinary justification for clinical testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bolton G (2003) Medicine, the arts, and the humanities. Lancet 362:93–94

    Article  PubMed  Google Scholar 

  2. Bourke B, Drumm B (2002) Cochrane’s epitaph for cisapride in childhood gastro-oesophageal reflux. Arch Dis Child 86:71–72

    Article  CAS  PubMed  Google Scholar 

  3. Diggle T, McConachie HR, Randle VRL (2003) Parent-mediated early intervention for young children with autism spectrum disorder. Cochrane Database Systematic Reviews 1:CD003496

    Google Scholar 

  4. Dunn-Geier J, Ho HH, Auersperg E, Doyle D, Eaves L, Matsuba C, Orrbine E, Pham B, Whiting S (2000) Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol 42:796–802

    Article  CAS  PubMed  Google Scholar 

  5. Green J, Britten N (1998) Qualitative research and evidence based medicine. BMJ 316:1230–1232

    CAS  PubMed  Google Scholar 

  6. Greenhalgh T (1997) How to read a paper: assessing the methodological quality of published papers. BMJ 315:305–308

    CAS  PubMed  Google Scholar 

  7. Greenhalgh T (1999) Narrative based medicine: narrative based medicine in an evidence based world. BMJ 318:323–325

    CAS  PubMed  Google Scholar 

  8. Griffiths KM, Christensen H (2000) Quality of web based information on treatment of depression: cross sectional survey. BMJ 321:1511–1515

    Article  CAS  PubMed  Google Scholar 

  9. Hey E (2002) Clinical trials: when to start and when to stop. Lancet 359:1449

    Article  PubMed  Google Scholar 

  10. Horng S, Miller FG (2002) Is placebo surgery unethical? N Engl J Med 347:137–139

    Article  PubMed  Google Scholar 

  11. Ijichi S, Ijichi N (2002) Ignorance of Helsinki Declaration. Lancet 360:415

    Article  Google Scholar 

  12. Ijichi S, Ijichi N (2003) Beyond negative data in autism randomized trials. Autism: in press

  13. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807–811

    PubMed  Google Scholar 

  14. Lang DA, Neil-Dwyer G (2001) Principles and problems of assessing the results of medical treatment. Acta Neurochir Suppl 78:59–62

    CAS  PubMed  Google Scholar 

  15. Lord C, Cook EH, Leventhal BL, Amaral DG (2000) Autism spectrum disorders. Neuron 28:355–363

    CAS  PubMed  Google Scholar 

  16. Meakins JL (2002) Innovation in surgery: the rules of evidence. Am J Surg 183:399–405

    Article  PubMed  Google Scholar 

  17. Nakane Y (1995) Pharmacotherapy of mental disorders in childhood and adolescence. Korean J Psychopharmacol 6:111–125

    Google Scholar 

  18. Rosselli D, Otero A (2002) The case report is far from dead (Letter). Lancet 359:84

    Article  Google Scholar 

  19. Schrot R, Muizelaar JP (2002) Mannitol in acute traumatic brain injury. Lancet 359:1633–1634

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shinji Ijichi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ijichi, S., Ijichi, N. The scientific establishment of a new therapeutic intervention for developmental conditions: practical and ethical principles. Childs Nerv Syst 19, 711–715 (2003). https://doi.org/10.1007/s00381-003-0846-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-003-0846-6

Keywords

Navigation